कंपनी का अवलोकन
KORU Medical Systems, Inc. is a specialized manufacturer focused on the development, production, and commercialization of subcutaneous infusion solutions designed primarily for the subcutaneous drug delivery market within the United States and international regions. The corporation operates within the Healthcare sector, specifically functioning inside the Medical Instruments & Supplies industry, which denotes its reliance on advanced medical technology to address patient needs for chronic illness therapies. The company's current operational scale is characterized by a market capitalization of $202.64M, an annual revenue of $41.13M, and an employed workforce of 73 individuals. These valuation and revenue figures indicate that KORU Medical Systems maintains a small-cap market position, suggesting it is a niche player with limited market penetration compared to large-cap pharmaceutical giants, yet it possesses a specialized product portfolio that allows for focused commercialization efforts in the infusion therapy space.
वित्तीय स्वास्थ्य
The financial performance metrics for the trailing twelve months reveal a revenue stream of $41.13M, which stands in stark contrast to a net income of $-2,637,926, while the EBITDA stands at $-2,279,840. The significant gap between the positive revenue figure and the negative net income highlights a substantial cost structure burden, where operating expenses and taxes consume the majority of the generated income, resulting in a profit margin of -6.4%. Despite the accounting loss, the company demonstrates a degree of operational efficiency by generating positive Free Cash Flow of $385,832, which provides essential financial flexibility to fund operations without immediate reliance on external equity financing. The gross margin stands at 62.3%, indicating high pricing power or low cost of goods sold relative to revenue, yet this is offset by an operating margin of -5.0%, suggesting that administrative and selling expenses are eroding the gross profits significantly. In terms of liquidity and leverage, the company holds $8.87M in cash against total debt of $3.50M, resulting in a conservative debt-to-equity ratio of 20.51%. The current ratio is recorded at 2.44, which indicates a robust short-term liquidity position where current assets are more than twice the current liabilities. Furthermore, the Return on Equity is -15.6% and the Return on Assets is -6.7%, metrics that collectively reveal that management is currently unable to generate positive returns on the capital invested by shareholders or utilized in assets, reflecting a period of investment or restructuring rather than mature profitability.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is projected at 51.41. The disparity between a non-existent trailing P/E and a high forward P/E implies that the market expects a substantial turnaround in earnings trajectory to justify the current share price in the future. The price-to-book ratio is 11.88, which indicates a significant market premium over the company's tangible book value, suggesting investors are pricing in future growth potential or specific intangible assets not reflected on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 4.93 and an EV/EBITDA of -86.53 suggest that traditional multiple-based comparisons are difficult, as the negative EV/EBITDA reflects the current unprofitability. The stock has traded within a range defined by a 52-week high of $6.61 and a 52-week low of $1.86, meaning the current price sits significantly below the yearly peak but has recovered from the yearly trough. The beta value is 0.54, which explains that the stock exhibits lower price volatility relative to the broader market, moving less aggressively than the overall market index during periods of fluctuation.
Growth & Income
The revenue growth year-over-year is recorded at 23.3%, while the earnings growth year-over-year is N/A due to the company's current losses. The fact that earnings growth is not positive while revenue is expanding rapidly implies that the company is still in a phase where top-line expansion has not yet translated into bottom-line profitability, likely due to high initial investment costs or scaling challenges. Since KORU Medical Systems, Inc. does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the company reinvests all available cash flows back into the business rather than distributing income to shareholders. This strategy is typical for growth-stage companies that prioritize capital expenditure and research over income generation. Overall, the growth and income profile is defined by strong top-line expansion coupled with a complete absence of dividend income, reflecting a high-risk, high-reward capital allocation strategy focused on future market capture rather than current shareholder yield.